Neurosarcoidosis:Signs, Course and Treatment in 35 Confirmed Cases
Medicine 69:261-276, Chapelon,C.,et al, 1990
Cortical Blindness:Etiology, Diagnosis, & Prognosis
Ann Neurol 21:149-158, Aldrich,M.S.,et al, 1987
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009
A Man Who Lost Weight and His Sight
Lancet 351:1174-1175, Moschos,M.&Droutsas,D., 1998
Visual Evoked Potential in Adrenoleukodystrophy:Glycerol Trioleate and Lorenzo Oil
Ann Neurol 34:169-174, 1211993., Kaplan,P.W.,et al, 1993
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Evoked Potentials in Cerebrotendinous Xanthomatosis and Effect Induced by Chenodeoxycholic Acid
Arch Neurol 49:469-475, Mondelli,M.,et al, 1992
Longitudinal Neurophysiologic Studies in Pt with Metachromatic Leukodystrophy Following Bone Marrow Trnspl
Arch Neurol 49:1088-1092, Dhuna,A.,et al, 1992
Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Visual & Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
NEJM 314:869-873, Olivieri,N.F.,et al, 1986
Toluene Optic Neuropathy
Ann Neurol 4:390, Keane,J.R., 1978
Subclinical Optic Neuropathy in Multiple Sclerosis
Arch Neurol 34:666, Galvin,R.J.,et al, 1977